Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 1
Submit an article Journal homepage
272
Views
64
CrossRef citations to date
0
Altmetric
Review

Cell-based models to study hepatic drug metabolism and enzyme induction in humans

Marc Vermeir Johnson & Johnson Pharmaceutical Research & Development, Preclinical Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium. [email protected]
,
Pieter Annaert Johnson & Johnson Pharmaceutical Research & Development, Preclinical Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium. [email protected]
,
Rao NVS Mamidi Johnson & Johnson Pharmaceutical Research & Development, Preclinical Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium. [email protected]
,
Dirk Roymans Lead Discovery Operations, Tibotec bvba, Generaal De Wittelaan 11B3, B-2800 Mechelen, Belgium
,
Willem Meuldermans Johnson & Johnson Pharmaceutical Research & Development, Preclinical Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium. [email protected]
&
Geert Mannens Johnson & Johnson Pharmaceutical Research & Development, Preclinical Pharmacokinetics, Turnhoutseweg 30, B-2340 Beerse, Belgium. [email protected]
Pages 75-90 | Published online: 14 Jun 2005

Bibliography

  • VENKATAKRISHNAN K, VON MOLTKE LL, GREENBLATT DJ: Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. (2001) 41(11):1149–1179.
  • MACGREGOR JT, COLLINS JM, SUGIYAMA Y et al.: In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. (2001) 59(1):17–36.
  • LIN JH, LU AY: Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Ann. Rev. Pharmacol. Toxicol. (2001) 41:535–567.
  • CERVENKOVA K, BELEJOVA M, VESELY J et al.: Cell suspensions, cell cultures, and tissue slices - important metabolic in vitro systems. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. (2001) 145(2):57–60.
  • LECLUYSE EL, ALEXANDRE E, HAMILTON GA et al. : Isolation and culture of primary human hepatocytes. Methods Mol. Biol. (2005) 290:207–229.
  • MCGINNITY DF, SOARS MG, URBANOWICZ RA, RILEY RJ: Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. (2004) 32(11):1247–1253.
  • EKINS S, RING BJ, GRACE J, MCROBIE-BELLE DJ, WRIGHTON SA: Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods (2000) 44(1):313–324.
  • BRANDON EF, RAAP CD, MEIJERMAN I, BEIJNEN JH, SCHELLENS JH: An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. (2003) 189(3):233–246.
  • GOMEZ-LECHON MJ, DONATO MT, CASTELL JV, JOVER R: Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. (2004) 5(5):443–462.
  • PLANT N: Strategies for using in vitro screens in drug metabolism. Drug Discov. Today (2004) 9(7): 328–336.
  • CROSS DM, BAYLISS MK: A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development. Drug Metab. Rev. (2000) 32(2):219–240.
  • SINZ M: In vitro metabolism: hepatocytes. In: Handbook of Drug Metabolism. TF Woolf (Ed.), Marcel Dekker, Inc., New York, USA (1999):401–424.
  • GOMEZ-LECHON MJ, DONATO MT, CASTELL JV, JOVER R: Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. (2003) 4(4):292–312.
  • PARKINSON A, MUDRA DR, JOHNSON C, DWYER A, CARROLL KM: The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. (2004) 199(3):193–209.
  • BJORNSSON TD, CALLAGHAN JT, EINOLF HJ et al. : The conduct of in vitro and in vivo drug—drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. (2003) 31(7):815–832.
  • LECLUYSE EL: Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. (2001) 13(4):343–368.
  • WORBOYS PD, CARLILE DJ: Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica (2001) 31(8–9):539–556.
  • LI AP, GORYCKI PD, HENGSTLER JG et al.: Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem. Biol. Interact. (1999) 121(1):117–123.
  • LLOYD TD, ORR S, SKETT P, BERRY DP, DENNISON AR: Cryopreservation of hepatocytes: a review of current methods for banking. Cell Tissue Bank. (2003) 4(1):3–15.
  • REDER-HILZ B, ULLRICH M, RINGEL M et al.: Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(4):408–417.
  • REINACH B, DE SOUSA G, DOSTERT P et al.: Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem. Biol. Interact. (1999) 121(1):37–48.
  • SILVA JM, DAY SH, NICOLL-GRIFFITH DA: Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes. Chem. Biol. Interact. (1999) 121(1):49–63.
  • SKETT P, ROBERTS P, KHAN S: Maintenance of steroid metabolism and hormone responsiveness in cryopreserved dog, monkey and human hepatocytes. Chem. Biol. Interact. (1999) 121(1):65–76.
  • HENGSTLER JG, UTESCH D, STEINBERG P et al.: Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab. Rev. (2000) 32(1):81–118.
  • ROYMANS D, VAN LOOVEREN C, LEONE A et al.: Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem. Pharmacol. (2004) 67(3):427–437.
  • ROYMANS D, ANNAERT P, VAN HOUDT J: Expression and Induction potential of cytochrome P450 in human cryopreserved hepatocytes. Drug Metab. Dispos. (2005) (in press).
  • LAZARO CA, CROAGER EJ, MITCHELL C et al.: Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology (2003) 38(5):1095–1106.
  • WRIGHTON SA, VANDENBRANDEN M: Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch. Biochem. Biophys. (1989) 268(1):144–151.
  • HAKKOLA J, RAUNIO H, PURKUNEN R et al.: Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate (2001) 80(3):193–201.
  • CHIBA M, XU X, NISHIME JA, BALANI SK, LIN JH: Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. (1997) 25(9):1022–1031.
  • WILLIAMS JA, RING BJ, CANTRELL VE et al. : Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. (2002) 30(8):883–891.
  • RAUCY JL, CARPENTER SJ: The expression of xenobiotic-metabolizing cytochromes P450 in fetal tissues. J. Pharmacol. Toxicol. Methods (1993) 29(3):121–128.
  • RING JA, GHABRIAL H, CHING MS, SMALLWOOD RA, MORGAN DJ: Fetal hepatic drug elimination. Pharmacol. Ther. (1999) 84(3):429–445.
  • HINES RN, MCCARVER DG: The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J. Pharmacol. Exp. Ther. (2002) 300(2):355–360.
  • MCCARVER DG, HINES RN: The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. (2002) 300(2):361–366.
  • MATSUNAGA T, MARUYAMA M, HARADA E et al.: Expression and induction of CYP3As in human fetal hepatocytes. Biochem. Biophys. Res. Commun. (2004) 318(2):428–434.
  • PENG DR, PACIFICI GM, RANE A: Human fetal liver cultures: basal activities and inducibility of epoxide hydrolases and aryl hydrocarbon hydroxylase. Biochem. Pharmacol (1984) 33(1):71–77.
  • MCELHATTON P: General principles of drug use in pregnancy. The Pharmaceutical Journal (2003) 270(7236):232–234.
  • INOUE C, YAMAMOTO H, NAKAMURA T, ICHIHARA A, OKAMOTO H: Nicotinamide prolongs survival of primary cultured hepatocytes without involving loss of hepatocyte-specific functions. J. Biol. Chem. (1989) 264(9):4747–4750.
  • KOST DP, MICHALOPOULOS GK: Effect of 2% dimethyl sulfoxide on the mitogenic properties of epidermal growth factor and hepatocyte growth factor in primary hepatocyte culture. J. Cell. Physiol. (1991) 147(2):274–280.
  • KATSURA N, IKAI I, MITAKA T et al.: Long-term culture of primary human hepatocytes with preservation of proliferative capacity and differentiated functions. J. Surg. Res. (2002) 106(1):115–123.
  • CHAN C, BERTHIAUME F, WASHIZU J, TONER M, YARMUSH ML: Metabolic preconditioning of cultured cells in physiological levels of insulin: generating resistance to the lipid-accumulating effects of plasma in hepatocytes. Biotechnol. Bioeng. (2002) 78(7):753–760.
  • RUNGE D, RUNGE DM, JAGER D et al.: Serum-free, long-term cultures of human hepatocytes: maintenance of cell morphology, transcription factors, and liverspecific functions. Biochem. Biophys. Res. Commun. (2000) 269(1):46–53.
  • LEE DH, YOON HH, LEE JH et al.: Enhanced liver-specific functions of endothelial cell-covered hepatocyte heterospheroids. Biochem. Eng. J. (2004) 20(2–3):181–187.
  • WATANABE T, SHIBATA N, WESTERMAN KA et al.: Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation (2003) 75(11):1873–1880.
  • KUDRYAVTSEVA EI, ENGELHARDT NV: Requirement of 3D extracellular network for maintenance of mature hepatocyte morphology and suppression of α-fetoprotein synthesis in vitro. Immunology Letters (2003) 90(1):25–31.
  • ZEILINGER K, SAUER IM, PLESS G et al.: Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. ATLA (2002) 30(5):525–538.
  • HARIMOTO M, YAMATO M, HIROSE M et al.: Novel approach for achieving double-layered cell sheets coculture: overlaying endothelial cell sheets onto monolayer hepatocytes utilizing temperature-responsive culture dishes. J. Biomed. Mater. Res. (2002) 62(3):464–470.
  • DONATO MT, CASTELL JV, GOMEZ-LECHON MJ: Co-cultures of hepatocytes with epithelial-like cell lines: expression of drug-biotransformation activities by hepatocytes. Cell Biol. Toxicol. (1991) 7(1):1–14.
  • DUNN JC, YARMUSH ML, KOEBE HG, TOMPKINS RG: Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration.[erratum appears in FASEB J 1989 May;3(7):1873]. FASEB J. (1989) 3(2):174–177.
  • GOMEZ-LECHON MJ, JOVER R, DONATO T et al. : Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell. Physiol. (1998) 177(4):553–562.
  • LECLUYSE EL, BULLOCK PL, PARKINSON A: Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Adv. Drug Del. Rev. (1996) 22(1–2):133–186.
  • LECLUYSE E, MADAN A, HAMILTON G et al. : Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol. (2000) 14(4):177–188.
  • KERN A, BADER A, PICHLMAYR R, SEWING KF: Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem. Pharmacol. (1997) 54(7):761–772.
  • KONO Y, YANG S, ROBERTS EA: Extended primary culture of human hepatocytes in a collagen gel sandwich system. In Vitro Cell Dev. Biol. Anim. (1997) 33(6):467–472.
  • COECKE S, ROGIERS V, BAYLISS M et al.: The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: the current status - ECVAM hepatocytes and metabolically competent systems task force report 1. ATLA (1999) 27(4):579–638.
  • DE SMET K, CAVIN C, VERCRUYSSE A, ROGIERS V: Collagen Type I gel cultures of adult rat hepatocytes as a screening induction model for cytochrome P450-dependent enzymes. ATLA (2001) 29(2):179–192.
  • TIPPIN TK, HAMILTON G, MOORE L et al.: CYP3A induction by N-hydroxyformamide tumor necrosis factor-α converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans. Drug Metab. Dispos. (2003) 31(7):870–877.
  • TREIJTEL N, BARENDREGT A, FREIDIG AP, BLAAUBOER BJ, VAN EIJKEREN JC: Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. (2004) 32(8):884–891.
  • ENGL T, BOOST KA, LECKEL K et al.: Phosphorylation of hepatocyte growth factor receptor and epidermal growth factor receptor of human hepatocytes can be maintained in a (3D) collagen sandwich culture system. Toxicol. In Vitro (2004) 18(4):527–532.
  • DEGLMANN CJ, EBNER T, LUDWIG E et al.: Protein binding capacity in vitro changes metabolism of substrates and influences the predictability of metabolic pathways in vivo. Toxicol. In Vitro (2004) 18(6):835–840.
  • NUSSLER AK, WANG A, NEUHAUS P et al.: The suitability of hepatocyte culture models to study various aspects of drug metabolism. Altex (2001) 18(2):91–101.
  • RINGEL M, VON MACH MA, SANTOS R et al.: Hepatocytes cultured in alginate microspheres: an optimized technique to study enzyme induction. Toxicology (2005) 206(1):153–167.
  • TONG JZ, SARRAZIN S, CASSIO D, GAUTHIER F, ALVAREZ F: Application of spheroid culture to human hepatocytes and maintenance of their differentiation. Biology of the Cell (1994) 81(1):77–81.
  • GEBHARDT R, HENGSTLER JG, MULLER D et al.: New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. (2003) 35(2–3):145–213.
  • GREUET J, PICHARD L, OURLIN JC et al. : Effect of cell density and epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture. Hepatology (1997) 25(5):1166–1175.
  • HAMILTON GA, JOLLEY SL, GILBERT D et al.: Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. (2001) 306(1):85–99.
  • DE KANTER R, MONSHOUWER M, MEIJER DK, GROOTHUIS GM: Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr. Drug Metab. (2002) 3(1):39–59.
  • LERCHE-LANGRAND C, TOUTAIN HJ: Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology (2000) 153(1–3):221–253.
  • CARLILE DJ, HAKOOZ N, HOUSTON JB: Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P450 activity. Drug Metab. Dispos. (1999) 27(4):526–532.
  • ANDERSSON TB, SJOBERG H, HOFFMANN KJ et al.: An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab. Dispos. (2001) 29(5):712–720.
  • VANDENBRANDEN M, WRIGHTON SA, EKINS S et al.: Alterations of the catalytic activities of drugmetabolizing enzymes in cultures of human liver slices. Drug Metab. Dispos. (1998) 26(11):1063–1068.
  • RENWICK AB, WATTS PS, EDWARDS RJ et al. : Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. (2000) 28(10):1202–1209.
  • EDWARDS RJ, PRICE RJ, WATTS PS et al. : Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. (2003) 31(3):282–288.
  • MARTIN H, SARSAT JP, DE WI et al. : Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm. Res. (2003) 20(4):557–568.
  • DE KANTER R, OLINGA P, HOF I et al.: A rapid and simple method for cryopreservation of human liver slices. Xenobiotica (1998) 28(3):225–234.
  • DAY SH, NICOLL-GRIFFITH DA, SILVA JM: Cryopreservation of rat and human liver slices by rapid freezing. Cryobiology (1999) 38(2):154–159.
  • GRANHALL C, FLOBY E, NORDMARK A et al.: Characterization of testosterone metabolism and 7-hydroxycoumarin conjugation by rat and human liver slices after storage in liquid nitrogen for 1 h up to 6 months. Xenobiotica (2002) 32(11):985–996.
  • CASCIO SM: Novel strategies for immortalization of human hepatocytes. Artif. Organs (2001) 25(7):529–538.
  • SELDEN C, HODGSON H: Cellular therapies for liver replacement. Transpl. Immunol. (2004) 12(3–4):273–288.
  • WERNER A, DUVAR S, MUTHING J et al.: Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. Biotechnol. Bioeng. (2000) 68(1):59–70.
  • GAO J, ANN GL, STORM SM et al. : Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol. In Vitro (2004) 18(4):533–541.
  • HORROCKS C, HALSE R, SUZUKI R, SHEPHERD PR: Human cell systems for drug discovery. Curr. Opin. Drug Discov. Devel. (2003) 6(4):570–575.
  • SMALLEY M, LEIPER K, TOOTLE R et al.: Immortalization of human hepatocytes by temperature-sensitive SV40 large-T antigen. In Vitro Cell Dev. Biol. Anim. (2001) 37(3):166–168.
  • KUNIEDA T, KOBAYASHI N, SAKAGUCHI M et al.: Transduction of immortalized human hepatocytes with p21 to enhance differentiated phenotypes. Cell Transplant. (2002) 11(5):421–428.
  • OBINATA M: Possible applications of conditionally immortalized tissue cell lines with differentiation functions. Biochem. Biophys. Res. Commun. (2001) 286(4):667–672.
  • KOBAYASHI N, FUJIWARA T, WESTERMAN KA et al.: Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science (2000) 287(5456):1258–1262.
  • KOBAYASHI N, WESTERMAN KA, TANAKA N, FOX IJ, LEBOULCH P: A reversibly immortalized human hepatocyte cell line as a source of hepatocyte-based biological support. Addict. Biol. (2001) 6(4):293–300.
  • OKITSU T, KOBAYASHI N, JUN HS et al.: Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. Diabetes (2004) 53(1):105–112.
  • INOUE Y, MIYAZAKI M, TSUJI T et al.: Reactivation of liver-specific gene expression in an immortalized human hepatocyte cell line by introduction of the human HNF4alpha2 gene. Int. J. Mol. Med. (2001) 8(5):481–487.
  • AKIYAMA I, TOMIYAMA K, SAKAGUCHI M et al.: Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor. Int. J. Mol. Med. (2004) 14(4):663–668.
  • SVANBERG A, DWYER JO, GOLDFARB P, SINDEN J: Development of novel human hepatocyte cell lines. 10th International Congress of Toxicology. Tampere, Finland (2004).
  • STEEN D: Immortalized human hepatocytes: a new advance in convenience and performance. Current Separations (2004) 20(4):137–140.
  • MILLS JB, ROSE KA, SADAGOPAN N, SAHI J, DE MORAIS SM: Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther. (2004) 309(1):303–309.
  • MASIMIREMBWA CM, OTTER C, BERG M et al.: Heterologous expression and kinetic characterization of human cytochromes P450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab. Dispos. (1999) 27(10):1117–1122.
  • GILLAM EM: Human cytochrome P450 enzymes expressed in bacteria - reagents to probe molecular interactions in toxicology. Clin. Exp. Pharmacol. Physiol. (1998) 25(11):877–886.
  • PARIKH A, GILLAM EM, GUENGERICH FP: Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnology (1997) 15(8):784–788.
  • PAINE MJ, GILHAM D, ROBERTS GC, WOLF CR: Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Arch. Biochem. Biophys. (1996) 328(1):143–150.
  • FRIEDBERG T, WOLF CR: Recombinant DNA technology as an investigative tool in drug metabolism research. Adv. Drug Del. Rev. (1996) 22(1–2):187–213.
  • RAUSCHENBACH R, GIESCHEN H, HUSEMANN M, SALOMON B, HILDEBRAND M: Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur. J. Pharmacol. (1995) 293(3):183–190.
  • YOKOI T, SAWADA M, KAMATAKI T: Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics (1995) 5:S65–S69.
  • GASSER R, FUNK C, MATZINGER P, KLEMISCH W, VIGER-CHOUGNET A: Use of transgenic cell lines in mechanistic studies of drug metabolism. Toxicol. In Vitro (1999) 13(4–5):625–632.
  • MCGINNITY DF, RILEY RJ: Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem. Soc. Trans. (2001) 29(Pt2):135–139.
  • COURT MH, DUAN SX, GUILLEMETTE C et al.: Stereoselective conjugation of oxazepam by human UDPglucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos. (2002) 30(11):1257–1265.
  • ANDREWS J, ABD-ELLAH MF, RANDOLPH NL et al.: Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica (2002) 32(11):937–947.
  • MCGINNITY DF, GRIFFIN SJ, MOODY GC et al.: Rapid characterization of the major drug-metabolizing human hepatic cytochrome P450 enzymes expressed in Escherichia coli. Drug Metab. Dispos. (1999) 27(9):1017–1023.
  • NAKAJIMA M, TANE K, NAKAMURA S et al.: Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. J. Pharm. Sci. (2002) 91(4):952–963.
  • IWATSUBO T, HIROTA N, OOIE T et al.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. (1997) 73(2):147–171.
  • RODRIGUEZ AD: Applications of heterologous expressed and purified human drug-metabolizing enzymes: an industrial perspective. In: Handbook of Drug Metabolism. TF Woolf (Ed.), Marcel Dekker, Inc., New York, USA (1999):279–319.
  • FRIEDBERG T, HENDERSON CJ, PRITCHARD MP, WOLF CR: In vivo and in vitro recombinant DNA technology as a powerful tool in drug development. In: Handbook of Drug Metabolism. TF Woolf (Ed.), Marcel Dekker, Inc., New York, USA (1999):321–361.
  • BRIMER C, DALTON JT, ZHU Z et al.: Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm. Res. (2000) 17(7):803–810.
  • BARON JM, GOH LB, YAO D, WOLF CR, FRIEDBERG T: Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping. J. Pharmacol. Exp. Ther. (2001) 296(2):351–358.
  • CRESPI CL, PENMAN BW, HU M: Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm. Res. (1996) 13(11):1635–1641.
  • SCHMIEDLIN-REN P, THUMMEL KE, FISHER JM et al.: Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3. Molecular Pharmacology (1997) 51(5):741–754.
  • CRESPI CL, FOX L, STOCKER P, HU M, STEIMEL DT: Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. Eur. J. Pharm. Sci. (2000) 12(1):63–68.
  • DAI Y, CEDERBAUM AI: Inactivation and degradation of human cytochrome P4502E1 by CCl4 in a transfected HepG2 cell line. J. Pharmacol. Exp. Ther. (1995) 275(3):1614–1622.
  • DOEHMER J: V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies. Toxicology (1993) 82(1–3):105–118.
  • OGG MS, WILLIAMS JM, TARBIT M et al.: A reporter gene assay to assess the molecular mechanisms of xenobioticdependent induction of the human CYP3A4 gene in vitro. Xenobiotica (1999) 29(3):269–279.
  • PLANT NJ, OGG M, CROWDER M, GIBSON GG: Control and statistical analysis of in vitro reporter gene assays. Anal. Biochem. (2000) 278(2):170–174.
  • RAUCY J, WARFE L, YUEH MF, ALLEN SW: A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J. Pharmacol. Exp. Ther. (2002) 303(1):412–423.
  • ETA J, YENGI L, XIANG Q, KAO J, SCATINA J: Establishment of a CYP3A4 reporter gene assay: validation using known CYP3A4 inducers, Wyeth compound tanaproget and comparator 3-ketodesogestrel. Drug Metab. Rev. (2005) 36(S1):188.
  • EL SANKARY W, GIBSON GG, AYRTON A, PLANT N: Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos. (2001) 29(11):1499–1504.
  • LUO G, CUNNINGHAM M, KIM S et al.: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. (2002) 30(7):795–804.
  • YUEH MF, KAWAHARA M, RAUCY J: High volume bioassays to assess CYP3A4- mediated drug interactions: induction and inhibition in a single cell line. Drug Metab. Dispos. (2005) 33(1):38–48.
  • YOUNG M, HUANG JJZ: Evaluation of a stably transfected human PXR cell line to determine potential 3A4 induction in human. Drug Metab. Rev. (2005) 36(S1):308.
  • LEMAIRE G, DE SOUSA G, RAHMANI R: A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem. Pharmacol (2004) 68(12):2347–2358.
  • SPINK BC, PANG S, PENTECOST BT, SPINK DC: Induction of cytochrome P450 1B1 in MDA-MB-231 human breast cancer cells by non-ortho-substituted polychlorinated biphenyls. Toxicol. In Vitro (2002) 16(6):695–704.
  • ALLEN SW, MUELLER L, WILLIAMS SN, QUATTROCHI LC, RAUCY J: The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human CYP1A1 expression. Drug Metab. Dispos. (2001) 29(8):1074–1079.
  • GALIJATOVIC A, OTAKE Y, WALLE UK, WALLE T: Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 29(12):1241–1256.
  • ALEXANDRE E, DAVID P, VIOLLON C et al.: Expression of cytochromes P450 2E1, 3A4 and 1A1/1A2 in growing and confluent human HepG2 hepatoma cells - effect of ethanol. Toxicol. In Vitro (1999) 13(3):427–435.
  • WALLE T, OTAKE Y, GALIJATOVIC A, RITTER JK, WALLE UK: Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab. Dispos. (2000) 28(9):1077–1082.
  • WILKENING S, STAHL F, BADER A: Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab. Dispos. (2003) 31(8):1035–1042.
  • HEWITT NJ, HEWITT P: Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica (2004) 34(3):243–256.
  • ELIZONDO G, MEDINA-DIAZ IM: Induction of CYP3A4 by 1alpha,25- dyhydroxyvitamin D3 in HepG2 cells. Life Sci. (2003) 73(2):141–149.
  • IWANARI M, NAKAJIMA M, KIZU R, HAYAKAWA K, YOKOI T: Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch. Toxicol. (2002) 76(5–6):287–298.
  • KRUSEKOPF S, ROOTS I, HILDEBRANDT AG, KLEEBERG U: Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica (2003) 33(2):107–118.
  • BAPIRO TE, ANDERSSON TB, OTTER C, HASLER JA, MASIMIREMBWA CM: Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur. J. Clin. Pharmacol. (2002) 58(8):537–542.
  • BALIHAROVA V, SKALOVA L, MAAS RF et al. : The effects of mebendazole on P4501A activity in rat hepatocytes and HepG2 cells. Comparison with tiabendazole and omeprazole. J. Pharm. Pharmacol. (2003) 55(6):773–781.
  • USUI T, SAITOH Y, KOMADA F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol. Pharm. Bull (2003) 26(4):510–517.
  • GOMEZ-LECHON MJ, DONATO T, JOVER R et al.: Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur. J. Biochem. (2001) 268(5):1448–1459.
  • JONES EA, TOSH D, FORRESTER LM: Liver. In: Handbook of Stem Cells (Volume 1). Embryonic Stem Cells. R Lanza, J Gearhart, B Hogan, D Melton, R Pedersen, J Thomson, M West (Eds), Elsevier Academic Press, New York, USA (2004):359–370.
  • GROMPE M: Adult Liver Stem Cells. In: Handbook of Stem Cells (Volume 2). Adult and Fetal Stem Cells. R Lanza, H Blau, D Melton, M Moore, TE Donall, C Verfaillie, I Weissmann, M West (Eds), Elsevier Academic Press, New York, USA (2004):483–495.
  • SHAY JW, WRIGHT WE: Hayflick, his limit, and cellular ageing. Nat. Rev. Mol. Cell Biol. (2000) 1(1):72–76.
  • SCHULDINER M, YANUKA O, ITSKOVITZ-ELDOR J, MELTON DA, BENVENISTY N: Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA (2000) 97(21):11307–11312.
  • RAMBHATLA L, CHIU CP, KUNDU P, PENG Y, CARPENTER MK: Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant. (2003) 12(1):1–11.
  • VESSEY CJ, DE LA HALL PM: Hepatic stem cells: a review. Pathology (2001) 33(2):130–141.
  • THEISE ND, NIMMAKAYALU M, GARDNER R et al.: Liver from bone marrow in humans. Hepatology (2000) 32(1):11–16.
  • PETERSEN BE, BOWEN WC, PATRENE KD et al.: Bone marrow as a potential source of hepatic oval cells. Science (1999) 284(5417):1168–1170.
  • ALISON MR, POULSOM R, JEFFERY R et al.: Hepatocytes from non-hepatic adult stem cells. Nature (2000) 406(6793):257.
  • LAGASSE E, CONNORS H, AL DHALIMY M et al.: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med (2000) 6(11):1229–1234.
  • LEE KD, KUO TK, WHANG-PENG J et al.: In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology (2004) 40(6):1275–1284.
  • SCHWARTZ RE, REYES M, KOODIE L et al.: Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. (2002) 109(10):1291–1302.
  • ZHAO Y, GLESNE D, HUBERMAN E: A human peripheral blood monocytederived subset acts as pluripotent stem cells. Proc. Natl. Acad. Sci. USA (2003) 100(5):2426–2431.
  • BARHAM HM, LENNARD MS, TUCKER GT: An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem. Pharmacol (1994) 47(8):1295–1307.
  • WU D, CEDERBAUM AI: Ethanol and arachidonic acid produce toxicity in hepatocytes from pyrazole-treated rats with high levels of CYP2E1. Mol. Cell Biochem. (2000) 204(1–2):157–167.
  • XIE W, BARWICK JL, DOWNES M et al.: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature (2000) 406(6794):435–439.
  • CORCHERO J, GRANVIL CP, AKIYAMA TE et al.: The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol. (2001) 60(6):1260–1267.
  • CHEUNG C, YU AM, WARD JM et al.: The CYP2E1 humanized transgenic mouse: role in acetaminophen hepatotoxicity. Drug Metab. Dispos. (2005) 33(3):449–457.
  • GRANVIL CP, YU AM, ELIZONDO G et al.: Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab. Dispos. (2003) 31(5):548–558.
  • LI Y, YOKOI T, KITAMURA R et al.: Establishment of transgenic mice carrying human fetus-specific CYP3A7. Arch. Biochem. Biophys. (1996) 329(2):235–240.
  • TATENO C, YOSHIZANE Y, SAITO N et al.: Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. (2004) 165(3):901–912.
  • KATOH M, MATSUI T, NAKAJIMA M et al.: Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos. (2004) 32(12):1402–1410.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.